Research
Hormonal
Glucagon-like peptide-1 (GLP-1) agonists lead to greater weight loss in clinical trials and real-world settings than orlistat.
GLP-1 agonists may be a more effective pharmacological option for weight management in patients with obesity and inflammatory skin conditions.
StrongSupportsmedium confidence
These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat.
Why this rating
The claim is based on clinical trials and real-world evidence.
Source
[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases
Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023
DOI 10.1016/j.ad.2023.10.019
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →